Semaglutide Laws by State: Does Your Weight-Loss Rule Cover GLP-1? (2026)
Most state rules on prescribing drugs for weight loss were written for phentermine and other controlled appetite suppressants. Semaglutide and tirzepatide aren't controlled, so most of those rules don't reach them. The rules in 5 states do: Alabama, Florida, Louisiana, Mississippi and New Jersey. Pick your state to see its rule, who can prescribe, and whether a telehealth-only start works there.
Compiled by Silver Taza. Last checked July 2026. General information, not legal advice.
What is true in every state
- Prescribing GLP-1 is the practice of medicine
- A licensed prescriber has to evaluate the patient and prescribe. There is no 'fill out a form and get a script': a real good-faith exam and a genuine provider-patient relationship are required everywhere.
- The drug has to be sourced legitimately
- That means an FDA-approved branded product, or compounding that fits both the narrow federal exceptions and your state's pharmacy rules. Mass-compounded semaglutide from the shortage era is largely no longer permitted.
- Estheticians and unlicensed staff do not prescribe
- Prescribing is for physicians, NPs, and PAs within their authority. Estheticians, cosmetologists, and other unlicensed staff cannot prescribe or decide who gets the medication.
- Who injects is broader than who prescribes
- A subcutaneous injection can usually be given by an RN, an LPN, or a medical assistant under delegation, on the prescriber's order. The prescribing decision, not the injection, is the regulated bottleneck.
- Most 'weight-loss rules' are about phentermine, not GLP-1
- Many states have prescribing rules for weight-reduction drugs, but most were written for controlled-substance appetite suppressants and don't reach GLP-1s, which aren't controlled. The lookup flags the few states whose rule does.
Compounded GLP-1s: a federal floor, plus your state's pharmacy rules
The FDA declared the tirzepatide shortage over in late 2024 and the semaglutide shortage over in February 2025, which ended the exception that let pharmacies mass-compound them. States then add their own compounding rules on top of that federal floor, and those differ from state to state. We don't track them here.
Check your state in The RX Index's compounded GLP-1 trackerWeight-loss prescribing rules change, and whether one applies turns on the drug, the prescriber, and your setup. Confirm the current rules with your state medical board and a healthcare attorney before you build or change a weight-loss program.
Weight-loss prescribing rules in all 50 states and DC
5 states have a weight-loss prescribing rule that reaches GLP-1 drugs. 15 have one that covers controlled drugs only, and in 30 we found no weight-loss rule at all. We couldn't confirm one.
The Source column links the rule itself. Where a state has no rule, it links the AANP practice-authority map, which the "Who can prescribe" column follows everywhere except Wisconsin, whose new APRN law took effect on September 1, 2026.
| State | Does the weight-loss rule reach GLP-1? | Who can prescribe | Telehealth-only start | Notes | Source |
|---|---|---|---|---|---|
| Alabama | Yes, the rule reaches GLP-1 | NP or PA with a physician | Limited or unsettled | Alabama's weight-loss rule has a section for non-controlled drugs such as GLP-1s. It allows five refills only after the first prescription and one in-person follow-up visit, and no refill past six months from the original prescription. NPs, PAs and midwives who prescribe non-controlled drugs for weight loss must follow the same chapter. The rest of the chapter covers controlled drugs. | |
| Alaska | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Arizona | No, controlled drugs only | NP on their own | Telehealth OK | Arizona treats prescribing amphetamines and similar Schedule II drugs for obesity for more than 30 days a year as unprofessional conduct. We found no rule that reaches GLP-1s. | |
| Arkansas | No, controlled drugs only | NP or PA with a physician | Telehealth OK | Arkansas's obesity rule covers Schedule III and IV drugs and bars Schedule II for obesity, so it doesn't reach GLP-1s. For non-controlled drugs, the medical board's Rule 2.8 lets a provider set up the patient relationship by telemedicine with access to the patient's health record, instead of an in-person exam. A questionnaire or email alone doesn't count. | |
| California | No weight-loss rule found | NP or PA with a physician | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Colorado | No, controlled drugs only | NP on their own | Telehealth OK | Colorado's medical board bars prescribing Schedule II stimulants for weight loss. GLP-1s aren't covered. | |
| Connecticut | No, controlled drugs only | NP on their own | Telehealth OK | Connecticut bars Schedule II sympathomimetic amines as appetite suppressants, except as state regulations allow. GLP-1s aren't covered. | |
| Delaware | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| District of Columbia | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Florida | Yes, the rule reaches GLP-1 | NP or PA with a physician | Telehealth OK | Florida's rule covers 'any drug' used for medically assisted weight loss, so it reaches GLP-1s. It sets a BMI floor (30, or over 27 with a comorbidity), requires an initial exam and written informed consent, a re-evaluation at least every 3 months, and a copy of the Weight-Loss Consumer Bill of Rights. The initial exam can be delegated to a PA or APRN. The osteopathic board has a matching rule. | |
| Georgia | No, controlled drugs only | NP or PA with a physician | Telehealth OK | Georgia limits Schedule II amphetamines and similar drugs to listed uses, one of which is weight loss with a drug the FDA approved for it. GLP-1s aren't covered. | |
| Hawaii | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Idaho | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Illinois | No weight-loss rule found | NP or PA with a physician | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Indiana | No, controlled drugs only | NP or PA with a physician | Telehealth OK | Indiana bars Schedule II drugs for weight reduction or obesity. GLP-1s aren't covered. | |
| Iowa | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Kansas | No, controlled drugs only | NP on their own | Telehealth OK | Kansas's obesity rule covers controlled substances only and bars amphetamines for obesity. GLP-1s aren't covered. | |
| Kentucky | No, controlled drugs only | NP or PA with a physician | Telehealth OK | Kentucky's rule covers amphetamine and amphetamine-like controlled appetite suppressants. GLP-1s aren't covered. | |
| Louisiana | Yes, the rule reaches GLP-1 | NP or PA with a physician | Telehealth OK | Louisiana bars physicians from using any drug for weight control unless the FDA approved it for treating obesity. That rules out off-label Ozempic or Mounjaro for weight loss; Wegovy and Zepbound, which carry the weight-management approval, are allowed. The exam and follow-up conditions in § 6907 cover only controlled appetite suppressants. | |
| Maine | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Maryland | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Massachusetts | No, controlled drugs only | NP on their own | Telehealth OK | Massachusetts bars prescribing any Schedule II controlled substance for its appetite-suppressing effect. GLP-1s aren't covered. | |
| Michigan | No weight-loss rule found | NP or PA with a physician | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Minnesota | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Mississippi | Yes, the rule reaches GLP-1 | NP or PA with a physician | Limited or unsettled |
Status in flux
Mississippi bars using any prescription drug for weight loss unless the FDA approved it for that, which rules out off-label semaglutide, and applies its diet-medication conditions to the drugs that qualify. Those start with a thorough history and a physical exam of the heart, lungs and abdomen before the first prescription, plus a BMI threshold. That exam is hard to do over video, so confirm with the board before running a telehealth-only program. | |
| Missouri | No weight-loss rule found | NP or PA with a physician | Telehealth OK | Missouri's only weight-loss rule declares HCG of no medical value for weight loss. Nothing reaches GLP-1s. | |
| Montana | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Nebraska | No, controlled drugs only | NP on their own | Telehealth OK | Nebraska treats prescribing Schedule II amphetamines for obesity for more than 30 days a year as unprofessional conduct. GLP-1s aren't covered. | |
| Nevada | No weight-loss rule found | NP on their own | Telehealth OK | Nevada repealed its appetite-suppressant rule in 2019. General prescribing rules apply. | |
| New Hampshire | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| New Jersey | Yes, the rule reaches GLP-1 | NP or PA with a physician | Limited or unsettled | New Jersey's rule for physicians in bariatric practice covers 'any drug for the treatment of obesity', so it reaches GLP-1s. It requires a complete history, a comprehensive physical exam and any indicated labs before prescribing, informed consent, nutrition and exercise counseling, and a physical exam at each follow-up visit. Another licensed practitioner can do the exams on the physician's order. | |
| New Mexico | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| New York | No, controlled drugs only | NP on their own | Telehealth OK | New York bars prescribing Schedule II amphetamines or similar drugs for the exclusive treatment of obesity or weight loss. GLP-1s aren't covered. | |
| North Carolina | No weight-loss rule found | NP or PA with a physician | Telehealth OK | North Carolina's medical board has a position statement on treating obesity, but it sets general standards (diet and exercise first, medication only when benefits outweigh risks) rather than drug-specific limits. | |
| North Dakota | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Ohio | No, controlled drugs only | NP or PA with a physician | Telehealth OK | Ohio's rule lets a prescriber use Schedule III or IV drugs for obesity only when the FDA approved them for it, and only under the rule's conditions. It covers controlled substances, so it doesn't reach GLP-1s. | |
| Oklahoma | Unclear | NP or PA with a physician | Telehealth OK |
Status in flux
We couldn't confirm whether Oklahoma has a weight-loss prescribing rule, so check with the medical board. | |
| Oregon | No, controlled drugs only | NP on their own | Telehealth OK | Oregon bars Schedule II drugs for weight reduction and limits Schedule III and IV drugs to the FDA's product guidelines. GLP-1s aren't covered. | |
| Pennsylvania | No weight-loss rule found | NP or PA with a physician | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Rhode Island | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule in Rhode Island's physician regulations. General prescribing rules apply. | |
| South Carolina | No weight-loss rule found | NP or PA with a physician | Telehealth OK | South Carolina's medical board regulations have no weight-loss prescribing rule. General prescribing rules apply. | |
| South Dakota | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Tennessee | No, controlled drugs only | NP or PA with a physician | Limited or unsettled | Tennessee's medical board restricts phentermine and other controlled appetite suppressants. GLP-1s aren't covered. The board requires an appropriate history and physical exam before prescribing but hasn't said whether it must be in person, so a telehealth-only start is unsettled. | |
| Texas | No weight-loss rule found | NP or PA with a physician | Telehealth OK | We found no weight-loss prescribing rule in the Texas Medical Board's rules. General prescribing rules apply. | |
| Utah | No, controlled drugs only | NP on their own | Telehealth OK | Utah bars Schedule II and III drugs for weight reduction and sets conditions for Schedule IV. GLP-1s aren't covered. | |
| Vermont | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Virginia | No weight-loss rule found | NP or PA with a physician | Telehealth OK | Virginia repealed its weight-loss prescribing rule effective February 27, 2025, and the matching rule for PAs is repealed too. General prescribing rules apply. | |
| Washington | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| West Virginia | No weight-loss rule found | NP or PA with a physician | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. | |
| Wisconsin | No weight-loss rule found | Depends on the NP | Telehealth OK |
Status in flux
We found no weight-loss prescribing rule in Wisconsin's current medical board code; the unprofessional-conduct rule lists none. Since September 1, 2026, an APRN who meets Act 17's requirements can prescribe without a collaborating physician; others still need one. | |
| Wyoming | No weight-loss rule found | NP on their own | Telehealth OK | We found no weight-loss prescribing rule here, so the general exam and standard-of-care rules apply. |
"Controlled drugs only" means the state has a weight-loss rule, but it covers phentermine and other scheduled drugs, not GLP-1s. "Limited or unsettled" means the state's rules call for in-person or physical exams that a telehealth-only program can't easily meet, or the board hasn't said. "Status in flux" means we couldn't confirm the rule or it just changed.
Why most weight-loss rules miss GLP-1 drugs
State medical boards wrote their weight-loss prescribing rules in the era of phentermine and amphetamine-type appetite suppressants, which are controlled substances. Most of them are limited, in their own text, to Schedule II, III or IV drugs used for weight loss. Semaglutide and tirzepatide aren't scheduled, so a rule written that way doesn't touch them. Your general duty to examine the patient and meet the standard of care still applies.
A few rules are written more broadly, and they are the ones that change how you run a GLP-1 program. Florida and New Jersey apply their weight-loss rules to any drug prescribed for weight loss, with exam, consent and follow-up requirements. Mississippi and Louisiana bar using a drug for weight loss unless the FDA approved it for that, which rules out prescribing Ozempic or Mounjaro off-label for weight loss. Alabama's rule allows refills of non-controlled weight-loss drugs only after an in-person follow-up visit, and caps them at six months.
Rules also disappear. Virginia repealed its weight-loss prescribing rule effective February 27, 2025, and Nevada repealed its appetite-suppressant rule in 2019. The table links each rule so you can read the current text yourself.
Who can prescribe
Prescribing GLP-1 for weight loss is the practice of medicine, so a licensed prescriber has to evaluate the patient and write the order. A physician can do that in every state. Whether a nurse practitioner or PA can prescribe on their own depends on the state's practice-authority rules: in a full-practice-authority state a nurse practitioner can run the prescribing side, and in the rest they need a collaborating or supervising physician.
Because GLP-1s are not controlled substances, this tracks the state's general nurse-practitioner prescribing authority rather than any special scheduling rule. Some weight-loss rules name NPs and PAs directly: Alabama's makes them follow the same chapter as physicians, and Florida's lets a physician delegate the initial exam to a PA or APRN.
Compounded GLP-1s: a federal floor, plus state rules
During the shortages, pharmacies could compound semaglutide and tirzepatide, and a wave of low-cost programs was built on that. The FDA declared the tirzepatide shortage over in late 2024 and the semaglutide shortage over in February 2025, and its grace periods for compounders ended in the first half of 2025. Compounding copies of these drugs is now limited to narrow, patient-specific cases.
That federal rule is only the floor. States add their own compounding rules on top. Since October 2025, California has required pharmacies to verify and document a clinically significant, patient-specific difference before compounding a copy of a commercial drug. Iowa's rule 481—552.22 bans compounding a copy of an FDA-approved drug unless the prescriber documents a clinically significant difference or the drug is in shortage. Indiana's SB 282 added rules on bulk ingredients, testing and records. We don't track these state by state; The RX Index keeps a 50-state tracker of compounded GLP-1 laws. Check your state there, and with its pharmacy board, before you build a program on compounded product.
How this fits with your other med-spa rules
A weight-loss program sits inside the wider question of who can own and run a medical practice in your state, and who can perform the medical services. If you also offer injectables, lasers, or IV therapy, the ownership, supervision, and administration rules for those matter alongside the prescribing rules here.
The IV therapy laws by state lookup covers who can order and administer IV drips. Neither page covers ownership or medical direction, so confirm all of it with your state boards and a healthcare attorney.
Frequently asked questions
Does my state's weight-loss prescribing rule apply to semaglutide?
In most states, no. Most state weight-loss rules were written for phentermine and other controlled appetite suppressants, and semaglutide and tirzepatide aren't controlled. Five states' rules do reach them. Florida and New Jersey apply their weight-loss rules to any drug prescribed for weight loss. Mississippi and Louisiana bar using a drug for weight loss unless the FDA approved it for that, which rules out off-label Ozempic. Alabama allows refills of non-controlled weight-loss drugs only after an in-person follow-up visit, and caps them at six months. Virginia repealed its weight-loss rule in February 2025.
Is compounded semaglutide still legal?
Only in narrow cases, and it isn't only a federal question. The FDA declared the tirzepatide shortage over in late 2024 and the semaglutide shortage over in February 2025, which ended the exception that let pharmacies mass-compound them. That federal rule is the floor. States add their own compounding rules on top: California, Iowa and Indiana, for example, each set their own conditions for compounded copies. Check your state's pharmacy rules, and The RX Index's state tracker, before you build a program around compounded product.
Who can prescribe semaglutide for weight loss?
A physician can everywhere, and whether a nurse practitioner or PA can prescribe on their own depends on your state. In a full-practice-authority state a nurse practitioner can evaluate, diagnose, and prescribe GLP-1 medication independently; in the rest they need a collaborating or supervising physician. GLP-1s are not controlled substances, so this tracks the state's general nurse-practitioner prescribing authority. The lookup shows which applies in your state, plus whether its weight-loss rule reaches GLP-1.
Can you prescribe semaglutide through telehealth?
Usually yes. GLP-1s are not controlled substances, so the in-person rules for prescribing controlled drugs over telehealth don't apply. A valid patient evaluation and a real provider-patient relationship are still required, and a live video visit can set that up in most states. A few states make a telehealth-only program harder: Mississippi's and New Jersey's weight-loss rules call for physical exams, Alabama's requires an in-person follow-up before refills, and Tennessee hasn't said whether its required exam can be remote. The table marks each state.
Do you need a doctor to run a semaglutide weight-loss business?
It depends on your state's nurse-practitioner rules and how you structure it. In a full-practice-authority state a nurse practitioner can run the prescribing side; elsewhere you need a collaborating or supervising physician, so that relationship has to be built into the business. On top of that, prescribing is the practice of medicine everywhere, so a real exam is required, the drug has to be sourced legitimately, and any state weight-loss prescribing rules apply. Confirm the setup with a healthcare attorney before you open.
Sources
Each state's rule is linked in the table above. These apply across states:
- AANP: State Practice Environment . The nurse-practitioner practice-authority map behind the NP column. GLP-1s aren't controlled, so general NP prescribing authority governs.
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize . The dates the FDA declared the tirzepatide and semaglutide shortages resolved, and when its compounding grace periods ended.
- The RX Index: Compounded GLP-1 Laws by State . A 50-state tracker of state rules on compounded GLP-1s, which this page doesn't cover.
- Iowa Admin. Code 481—552.22 (compounding) . An example of a state compounding rule: it bans compounding copies of an FDA-approved drug unless the prescriber documents a clinically significant difference or the drug is in shortage.